1. Expert proposal to characterize cardiac diseases with normal or preserved left ventricular ejection fraction and symptoms of heart failure by comprehensive echocardiography

   • A. Hagendorff
   • A. Helfen
   • S. Ewen

   Review Open access 04 June 2022 Pages: 1 - 38

   

2. Heart failure-related quality-of-life impairment after myocardial infarction

   • Peter Wohlfahrt
   • Dominik Jenča
   • Josef Kautzner

   Original Paper 18 March 2022 Pages: 39 - 48

   

3. Symptom burden, psychosocial distress and palliative care needs in heart failure – A cross-sectional explorative pilot study

   • F. Strangl
   • E. Ischanow
   • M. Rybczynski

   Original Paper Open access 14 April 2022 Pages: 49 - 58

   

4. Relationships between sympathetic markers and heart rate thresholds for cardiovascular risk in chronic heart failure

   • Guido Grassi
   • Gino Seravalle
   • Giuseppe Mancia

   Original Paper Open access 12 May 2022 Pages: 59 - 67

   

5. Reliability of estimating left ventricular ejection fraction in clinical routine: a validation study of the SWEDEHEART registry

   • Joel Lenell
   • Bertil Lindahl
   • Tomasz Baron

   Original Paper Open access 17 May 2022 Pages: 68 - 74

   

6. Lack of correlation between different congestion markers in acute decompensated heart failure

   • Svenja Haag
   • Alexander Jobs
   • Holger Thiele

   Original Paper Open access 01 June 2022 Pages: 75 - 86

   

7. Body fluid regulation via chronic inhibition of sodium–glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trial

   • Shinya Fujiki
   • Atsushi Tanaka
   • the CANDLE Trial Investigators

   Original Paper 22 June 2022 Pages: 87 - 97

   

8. Nighttime hemodynamic phenotype. A novel risk factor for cardiovascular disease, especially heart failure: the practitioner-based nationwide JAMP study

   • Kazuomi Kario
   • Satoshi Hoshide
   • the JAMP Study Group

   Original Paper 27 June 2022 Pages: 98 - 110

   

9. Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction

   • Sam Straw
   • Charlotte A. Cole
   • John Gierula

   Original Paper Open access 04 July 2022 Pages: 111 - 122

   

10. Comorbidities complicating heart failure: changes over the last 15 years

    • Elles M. Screever
    • Martje H. L. van der Wal
    • Wouter C. Meijers

    Original Paper Open access 17 August 2022 Pages: 123 - 133

    

11. The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial

    • Julie Kolwelter
    • Dennis Kannenkeril
    • Roland E. Schmieder

    Original Paper Open access 26 October 2022 Pages: 134 - 144

    

12. Clinical trajectories and outcomes of patients with heart failure with preserved ejection fraction with normal or indeterminate diastolic function

    • Bolrathanak Oeun
    • Shungo Hikoso
    • the OCVC-Heart Failure Investigators

    Original Paper 10 November 2022 Pages: 145 - 157

    

13. Defining the gap in heart failure treatment in patients with cardiac implantable electronic devices

    • Samaneh Salimian
    • Nima Moghaddam
    • Nathaniel M. Hawkins

    Original Paper 03 November 2022 Pages: 158 - 166

    

14. Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction

    • Michael Fu
    • Aldina Pivodic
    • Lars H. Lund

    Original Paper Open access 29 November 2022 Pages: 167 - 174

    

15. Correction: Relationships between sympathetic markers and heart rate thresholds for cardiovascular risk in chronic heart failure

    • Guido Grassi
    • Gino Seravalle
    • Giuseppe Mancia

    Correction Open access 23 November 2022 Pages: 175 - 175